Pfizer Inc. $PFE Shares Sold by Nelson Capital Management LLC

Key Points

• Nelson Capital Management LLC significantly reduced its stake in Pfizer by 90.2%, selling 82,620 shares and leaving it with 8,951 shares valued at $217,000.
• In contrast, other large investors like Pacer Advisors Inc. and Amundi increased their stakes in Pfizer, with Pacer Advisors acquiring shares valued at $508 million and Amundi at $1.27 billion during the first quarter.
• Pfizer recently reported a profit of $0.78 earnings per share for the last quarter, exceeding analysts' expectations and showing a 10.3% increase in revenue compared to the previous year.

Nelson Capital Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 90.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,951 shares of the biopharmaceutical company's stock after selling 82,620 shares during the period. Nelson Capital Management LLC's holdings in Pfizer were worth $217,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the period. Amundi increased its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC acquired a new position in shares of Pfizer during the 1st quarter valued at $389,861,000. Goldman Sachs Group Inc. increased its position in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after purchasing an additional 7,581,030 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.6%

Shares of Pfizer stock opened at $26.27 on Wednesday. The stock has a market capitalization of $149.36 billion, a P/E ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average price of $24.76 and a two-hundred day moving average price of $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on PFE shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Finally, UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and an average target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.